• Profile
Close

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology Dec 13, 2019

Mateo J, Porta N, Bianchini D, et al. - Researchers attempt at prospective confirmation of the link between DNA damage response (DDR) gene aberrations and response to olaparib in metastatic castration-resistant prostate cancer in the TOPARP-B trial. Participants were selected from 17 UK hospitals. Random allocation (1:1) of patients with DDR gene aberrations was done to administer 400 mg or 300 mg olaparib twice daily, delivered continuously in 4-week cycles until disease progression or unacceptable toxicity. Findings revealed the antitumour activity of olaparib against metastatic castration-resistant prostate cancer with DDR gene aberrations, and therefore, genomic stratification of metastatic castration-resistant prostate cancer in clinical practice was supported. In 15 [31%] of 49 patients in the 300 mg cohort and 18 [37%] of 49 in the 400 mg cohort, the occurrence of anaemia was reported, which was the most common grade 3–4 adverse event in both cohorts. A total of 13 patients suffered 19 serious adverse reactions.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay